SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 13,949.52 |
Enterprise Value ($M) | 13,561.72 |
Book Value ($M) | 388.70 |
Book Value / Share | 0.53 |
Price / Book | 35.89 |
NCAV ($M) | 365.40 |
NCAV / Share | 0.50 |
Price / NCAV | 38.18 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.53 |
Return on Assets (ROA) | -1.25 |
Return on Equity (ROE) | -5.01 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 9.88 |
Current Ratio | 9.88 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 412.30 |
Assets | 435.60 |
Liabilities | 46.90 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -211.00 |
Net Income | -221.30 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -142.10 |
Cash from Investing | -205.30 |
Cash from Financing | 381.20 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | Duggan Robert W | 75.20 | 216.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
780,239 | 3,680,418 | 21.20 | |
973,886 | 3,102,829 | 31.39 | |
451,397 | 2,047,886 | 22.04 | |
728,613 | 2,343,629 | 31.09 | |
757,591 | 1,946,349 | 38.92 | |
(click for more detail) |
Similar Companies | |
---|---|
SGMT – Sagimet Biosciences Inc. | SIGA – SIGA Technologies, Inc. |
SKYE – Skye Bioscience, Inc. | SPRY – ARS Pharmaceuticals, Inc. |
STRO – Sutro Biopharma, Inc. |
Financial data and stock pages provided by
Fintel.io